# ECHELON-2 (NCT01777152)

> ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01777152
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Seagen Inc.
- Conditions: Anaplastic Large-Cell Lymphoma; Non-Hodgkin Lymphoma; T-Cell Lymphoma
- Interventions: brentuximab vedotin; doxorubicin; prednisone; vincristine; cyclophosphamide
- Enrollment: 452
- Primary outcome: Progression-free Survival Per Independent Review Facility (IRF)

## Commentary we found

- YouTube: 12
- Podcasts: 8
- X threads: 8
- X videos: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=echelon-2-nct01777152

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01777152", "email": "<work email>"}; the inbox owner confirms by the emailed link.